Bio-Techne (TECH) Stock Price, News & Analysis

Company Overview

Bio-Techne Corporation is a life sciences company that develops and supplies research and diagnostic products for biotechnology, pharmaceutical, academic, clinical and other laboratory customers. The company supports biological research, drug discovery and development, and diagnostic testing through a portfolio of reagents, instruments and analytical technologies.

Its products include proteins, antibodies, immunoassays, flow cytometry reagents, molecular biology tools and cell culture materials. Bio-Techne also provides platforms for protein analysis, spatial biology, single-cell analysis, genomics and proteomics, as well as technologies used in cell and gene therapy development and manufacturing.

The company traces its origins to Techne Corporation, which was founded in 1976, and adopted the Bio-Techne name in 2014. Its brands have included R&D Systems, ProteinSimple, Advanced Cell Diagnostics, Novus Biologicals and Tocris. Bio-Techne serves customers internationally through operations and distribution networks supporting research and clinical applications worldwide.

Key Stats

• Today's Range: $72.51 to $72.69
• 50-Day Range: $72.08 to $72.64
• 52-Week Range: $43.19 to $72.69
• Volume: 4.16 million shs
• Average Volume: 2.83 million shs
• Market Capitalization: $11.39 billion
• P/E Ratio: 42.23
• Dividend Yield: 0.44%
• Price Target: $68.92
• Consensus Rating: Hold

Bio-Techne Stock Analysis - MarketRank™

Bio-Techne scored higher than 48% of companies evaluated by MarketBeat, and ranked 536th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Hold

Consensus Rating

Bio-Techne has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on no strong buy ratings, 2 buy ratings, 15 hold ratings, and no sell ratings.

Downside Risk

Bio-Techne has a consensus price target of $68.92, representing about 5.1% downside from its current price of $72.62.

Amount of Analyst Coverage

Bio-Techne has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.35%

Earnings Growth

Earnings for Bio-Techne are expected to grow by 12.35% in the coming year, from $1.70 to $1.91 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Techne is 42.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.47.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Techne is 42.23, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 192.96.

Price to Earnings Growth Ratio

Bio-Techne has a PEG Ratio of 8.97. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bio-Techne has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.77% of the float of Bio-Techne has been sold short.

Short Interest Ratio / Days to Cover

Bio-Techne has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Techne has recently increased by 11.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Bio-Techne has a dividend yield of 0.44%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bio-Techne does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Bio-Techne is 27.83%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.75% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.47

News Sentiment

Bio-Techne has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Bio-Techne this week, compared to 6 articles on an average week.

Search Interest

6 people have searched for TECH on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Techne insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.30% of the stock of Bio-Techne is held by insiders.

Percentage Held by Institutions

98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Record date for 8/28 Dividend: 8/17/2026
• Ex-Dividend for 8/28 Dividend: 8/17/2026
• Record date for 9/4 Dividend: 8/24/2026
• Ex-Dividend for 9/4 Dividend: 8/24/2026
• Dividend Payable: 8/28/2026
• Dividend Payable: 9/04/2026
• Today: 10/22/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TECH
• CIK: 842023
• Web: www.bio-techne.com
• Phone: (612) 379-8854
• Fax: 612-656-4400
• Employees: 3,000
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Bio-Techne: $68.92
• High Price Target: $79.00
• Low Price Target: $50.00
• Potential Upside/Downside: -5.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.12
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.15
• Trailing P/E Ratio: 42.23
• Forward P/E Ratio: 42.72
• P/E Growth: 8.97
• Net Income: $181.86 million
• Net Margins: 14.97%
• Pretax Margin: 19.81%
• Return on Equity: 13.23%
• Return on Assets: 10.61%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 4.55
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: $1.22 billion
• Price / Sales: 9.37
• Cash Flow: $2.35 per share
• Price / Cash Flow: 30.94
• Book Value: $13.47 per share
• Price / Book: 5.39

Miscellaneous

• Outstanding Shares: 156,820,000
• Free Float: 154,779,000
• Market Cap: $11.39 billion
• Optionable: Optionable
• Beta: 1.30